Accord Signs Agreement to Acquire Prothya Biosolutions
Deal News | Aug 11, 2025 | PR Newswire Cision Accord Healthcare
Intas Pharmaceuticals' subsidiary, Accord Plasma B.V., has agreed to acquire Prothya Biosolutions Belgium BV, a leading plasma-derived medicinal products (PDMP) company. This strategic acquisition is a significant step for Intas and Accord to establish a global presence in the PDMP market. Subject to regulatory approvals, the deal is expected to close soon. Prothya, operating primarily in the Netherlands and Belgium, employs approximately 1,200 people and has a comprehensive network, including plasma collection centers across Hungary. Established in 2021 by integrating Plasma Industries Belgium and Sanquin Plasma Products, Prothya brings over 60 years of experience in plasma collection and PDMP development. Binish Chudgar, President of Intas & Accord, expressed enthusiasm for creating a truly global platform for plasma through this acquisition. Prothya's CEO, Nir Epstein, highlighted the company's recent expansion and achievements, expressing confidence that Accord is the right partner for future growth. The global PDMP market is valued at $30 billion, with expectations to reach $50 billion by 2035. Advisers for this transaction include BofA Securities for Accord and Evercore for Prothya.
Sectors
- Pharmaceuticals
- Healthcare
Geography
- India – Intas Pharmaceuticals, the acquiring company, is based in Ahmedabad, India.
- Belgium – Prothya Biosolutions, the target company, is headquartered in Belgium.
- Netherlands – Prothya Biosolutions has its primary operations in the Netherlands.
- Hungary – Prothya Biosolutions operates plasma collection centers in Hungary.
Industry
- Pharmaceuticals – The article discusses the acquisition of Prothya Biosolutions by Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, indicating the focus on the pharmaceutical sector.
- Healthcare – The transaction involves the acquisition of a company engaged in plasma-derived medicinal products, tying it to the healthcare industry.
Financials
- $30 billion – The current valuation of the global PDMP market, expected to grow to $50 billion by 2035.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Intas Pharmaceuticals Ltd. | Acquiring Company | Company | A leading vertically integrated pharmaceutical company based in India. |
| Accord Plasma B.V. | Acquiring Company/Subsidiary | Company | A subsidiary of Intas Pharmaceuticals involved in the acquisition. |
| Prothya Biosolutions Belgium BV | Target Company | Company | A leader in plasma-derived medicinal products with operations in Belgium and the Netherlands. |
| BofA Securities | Financial Advisor to the Acquirer | Company | Advising Accord on the acquisition transaction. |
| Evercore | Financial Advisor to the Target | Company | Advising Prothya in the acquisition deal. |